Navigation Links
Shareholders of Med-Emerg International Inc. approve plan of arrangement with AIM Health Group Inc.
Date:1/8/2009

TORONTO, Jan. 8 /PRNewswire-FirstCall/ - Med-Emerg International Inc. (OTCBB:MDER) ("MedEmerg"), one of Canada's leading providers of health services, is pleased to announce that its shareholders have voted in favour of the previously announced plan of arrangement (the "Arrangement") with AIM Health Group Inc. ("AIM") at a special meeting of MedEmerg's shareholders held in Toronto today. In excess of 90% of the votes cast at the meeting were in favour of the Arrangement.

The completion of the Arrangement remains subject to a final hearing by the Ontario Superior Court of Justice, currently expected to take place on January 13, 2009, and satisfaction of certain additional closing conditions.

About Med-Emerg International Inc.

MedEmerg specializes in the coordination and delivery of health care services in Canada. These services include an integrated chronic pain management program, community-based infusion centers and health human resource management, including physician and nurse staffing.

MedEmerg's audited revenue for its fiscal year ended December 31, 2007 was approximately US$22 million.

(www.medemerg.com)

Caution Concerning Forward-Looking Statements

Certain statements in this press release are forward-looking statements, including, but not limited to, those relating to the proposed transaction, the timing of the closing of the proposed transaction and other statements that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "plan", "expect", "believe", "intend", "anticipate", "forecast", "target", "estimate" and similar expressions identify forward-looking statements. Forward-looking statements are based on assumptions made by and information currently available to MedEmerg. Investors are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These risks and uncertainties are outlined in MedEmerg's Annual Report on Form 10-K for 2007, and such other documents as are filed with the Securities and Exchange Commission from time to time. MedEmerg does not undertake to review or update these forward-looking statements. MedEmerg qualifies all of the information contained in this press release, and particularly its forward-looking statements, by these cautionary statements.

Additional information about the risks and uncertainties of AIM's and MedEmerg's business is provided in their respective disclosure materials filed with the securities regulatory authorities in Canada, available at www.sedar.com.


'/>"/>
SOURCE Med-Emerg International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
3. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
4. United Medicorp, Inc.s Shareholders Approve All Proposals
5. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
6. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
7. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
8. Flextronics Shareholders and Solectron Stockholders Approve Acquisition
9. Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction
10. Lafley Tells Shareholders That P&G is Designed to Grow
11. Manor Care Shareholders Vote to Approve $6.3 Billion Carlyle Buyout
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: